QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
NASDAQ:ZIOP

ZIOPHARM Oncology Stock Forecast, Price & News

$1.26
+0.04 (+3.28%)
(As of 12/6/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.20
$1.29
50-Day Range
$1.22
$2.12
52-Week Range
$1.20
$5.95
Volume
2.00 million shs
Average Volume
2.51 million shs
Market Capitalization
$272.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.77
30 days | 90 days | 365 days | Advanced Chart
Receive ZIOP News and Ratings via Email

Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter.


ZIOPHARM Oncology logo

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ZIOP
CUSIP
98973P10
Employees
105
Year Founded
2005

Sales & Book Value

Annual Sales
$150 thousand
Book Value
$0.32 per share

Profitability

Net Income
$-79.98 million
Pretax Margin
-22,544.97%

Debt

Price-To-Earnings

Miscellaneous

Free Float
204,906,000
Market Cap
$272.34 million
Optionable
Optionable

Company Calendar

Last Earnings
11/08/2021
Today
12/06/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

Social Links


MarketRank

Overall MarketRank

2.10 out of 5 stars

Medical Sector

513th out of 1,390 stocks

Pharmaceutical Preparations Industry

241st out of 673 stocks

Analyst Opinion: 3.1Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












ZIOPHARM Oncology (NASDAQ:ZIOP) Frequently Asked Questions

Is ZIOPHARM Oncology a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ZIOPHARM Oncology in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ZIOPHARM Oncology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZIOP, but not buy additional shares or sell existing shares.
View analyst ratings for ZIOPHARM Oncology
or view top-rated stocks.

How has ZIOPHARM Oncology's stock been impacted by COVID-19?

ZIOPHARM Oncology's stock was trading at $2.54 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ZIOP shares have decreased by 50.4% and is now trading at $1.26.
View which stocks have been most impacted by COVID-19
.

When is ZIOPHARM Oncology's next earnings date?

ZIOPHARM Oncology is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for ZIOPHARM Oncology
.

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) announced its earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04. The biotechnology company had revenue of $0.40 million for the quarter. During the same quarter last year, the business earned ($0.10) EPS.
View ZIOPHARM Oncology's earnings history
.

What price target have analysts set for ZIOP?

4 analysts have issued 1 year price targets for ZIOPHARM Oncology's shares. Their forecasts range from $2.00 to $5.00. On average, they anticipate ZIOPHARM Oncology's share price to reach $3.50 in the next year. This suggests a possible upside of 177.8% from the stock's current price.
View analysts' price targets for ZIOPHARM Oncology
or view top-rated stocks among Wall Street analysts.

Who are ZIOPHARM Oncology's key executives?

ZIOPHARM Oncology's management team includes the following people:
  • Kevin S. Boyle, Chief Executive Officer & Director (LinkedIn Profile)
  • Timothy M. Cunningham, Chief Financial Officer
  • Lynn M. Ferrucci, EVP-Human Resources, Administration & IT
  • Raffaele Baffa, Chief Medical Officer & Head-Research
  • Eleanor M. de Groot, General Manager-Cell Therapy & Executive VP

What other stocks do shareholders of ZIOPHARM Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN), Gilead Sciences (gild), OPKO Health (OPK), (CELG), Sangamo Therapeutics (SGMO), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Inovio Pharmaceuticals (INO), Arena Pharmaceuticals (ARNA) and Immunomedics (IMMU).

What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

Who are ZIOPHARM Oncology's major shareholders?

ZIOPHARM Oncology's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.86%), Geode Capital Management LLC (1.55%), Renaissance Technologies LLC (0.68%), Point72 Asset Management L.P. (0.63%), Two Sigma Advisers LP (0.49%) and Millennium Management LLC (0.45%). Company insiders that own ZIOPHARM Oncology stock include David M Md Mauney, Groot Eleanor De, Heidi Hagen, Jaime Vieser, Jill Buck, Kevin G Lafond, Kevin S Sr Boyle, Laurence James Neil Cooper and Robert Hadfield.
View institutional ownership trends for ZIOPHARM Oncology
.

Which major investors are selling ZIOPHARM Oncology stock?

ZIOP stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Two Sigma Investments LP, Geode Capital Management LLC, Morgan Stanley, Dimensional Fund Advisors LP, Jane Street Group LLC, New York State Common Retirement Fund, and Oppenheimer & Co. Inc.. Company insiders that have sold ZIOPHARM Oncology company stock in the last year include Groot Eleanor De, Jill Buck, Kevin G Lafond, Laurence James Neil Cooper, and Robert Hadfield.
View insider buying and selling activity for ZIOPHARM Oncology
or view top insider-selling stocks.

Which major investors are buying ZIOPHARM Oncology stock?

ZIOP stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Millennium Management LLC, BlackRock Inc., Renaissance Technologies LLC, Marshall Wace LLP, UBS Group AG, Tudor Investment Corp Et Al, and State Board of Administration of Florida Retirement System. Company insiders that have bought ZIOPHARM Oncology stock in the last two years include Heidi Hagen, Jaime Vieser, and Kevin S Sr Boyle.
View insider buying and selling activity for ZIOPHARM Oncology
or or view top insider-buying stocks.

How do I buy shares of ZIOPHARM Oncology?

Shares of ZIOP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ZIOPHARM Oncology's stock price today?

One share of ZIOP stock can currently be purchased for approximately $1.26.

How much money does ZIOPHARM Oncology make?

ZIOPHARM Oncology has a market capitalization of $272.34 million and generates $150 thousand in revenue each year. The biotechnology company earns $-79.98 million in net income (profit) each year or ($0.43) on an earnings per share basis.

How many employees does ZIOPHARM Oncology have?

ZIOPHARM Oncology employs 105 workers across the globe.

When was ZIOPHARM Oncology founded?

ZIOPHARM Oncology was founded in 2005.

What is ZIOPHARM Oncology's official website?

The official website for ZIOPHARM Oncology is www.ziopharm.com.

Where are ZIOPHARM Oncology's headquarters?

ZIOPHARM Oncology is headquartered at ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129.

How can I contact ZIOPHARM Oncology?

ZIOPHARM Oncology's mailing address is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. The biotechnology company can be reached via phone at (617) 259-1970, via email at [email protected], or via fax at 617-241-2855.


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.